Developed skills and lines of research

Adriana Chilin graduated in Chemistry and Pharmaceutical Technology from the University of Padua, Italy, in 1983, and then obtained her PhD in Pharmaceutical Sciences from the same university in 1988. From 1989 to 2000 she was a research fellow in the Faculty of Pharmacy at the University of Padua; since 2000 she has been an Associate Professor of Pharmaceutical Chemistry in the Faculty of Pharmacy – now School of Medicine – at the University of Padua. The research topics she has addressed over the years are the design, synthesis and study of chemical compounds relevant for their specific functions. In fact, for cystic fibrosis she has been involved in synthesizing Trimethylangelicin (TMA) analogous molecules capable of acting selectively as correctors/potentiators of CFTR or as anti-inflammatory agents, devoid of the unfavorable side effects of TMA. Her laboratory is also active in the identification of organic compounds by 1H-NMR and 13C-NMR spectroscopy and mass spectrometry. She is the author of more than 70 international publications and co-inventor of 4 patents.

Projects funded by FFC Ricerca as Principal Investigator or as Research Manager

FFC#3/2021
Toward the development of tailored therapies for insensitive CF gating mutations

FFC#1/2016
New generation trimethylangelicin (TMA) analogues for selective modulation of defective CFTR or inflammation

Projects financed by FFC Ricerca as a partner

FFC#22/2019
Multi-task evaluation of TMA analogues as anti-inflammatory treatments for CF lung disease

FFC#8/2014
Design and synthesis of improved analogs of trimethylangelicin (TMA) for personalized treatment of cystic fibrosis

Publications from FFC Research projects

I Lampronti, MG Manzione, G Sacche et al. Differential Effects of Angelicin Analogues on NF-κB Activity and IL-8 Gene Expression in Cystic Fibrosis IB3-1 Cells. Mediators Inflamm. 2017; 2017: 2389487.  Published online 2017 Sep 27.  doi:  10.1155/2017/2389487

Laselva O, Marzaro G, Vaccarin C, et al., Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators. Front Pharmacol. 2018 Jul 4;9:719. doi: 10.3389/fphar.2018.00719. eCollection 2018.

Marzaro G, Lampronti I, D’Aversa E, et al., Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB). Eur J Med Chem. 2018 May 10;151:285-293. doi: 10.1016/j.ejmech.2018.03.080. Epub 2018 Mar 31.

Adriana Chilin, Roberto Gambari, Ilaria Lampronti, Giulio Cabrini, Maria Cristina Dechecchi. New generation trimethylangelicin (TMA) analogues for selective modulation of defective CFTR or inflammation. The Proceedings of the 16th Italian Convention of Investigators in Cystic Fibrosis. Multidisciplinary Respiratory Medicine, 2019, 14 (Suppl 1):5